BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
February 23, 2022 7:00 AM ESTQ4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021
ORLADEYO net revenue in 2022 expected to be no less than $250 million
Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... More
